Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study

NCT02623569 is registered in ClinicalTrials.gov with Xintong Pharmacy Company as lead sponsor.

NCT NCT02623569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02623569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study
Lead sponsor
Xintong Pharmacy Company
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2014
Completion date
June 30, 2017
Enrollment
336 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris